Showing 5371-5380 of 8973 results for "".
- ASDS Survey Finds Consumers Prefer Its Membershttps://practicaldermatology.com/news/asds-survey-finds-consumers-prefer-its-members/2458882/The 2015 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical treatments and ratings for 10 specific procedures – shows the majority of respondents in eight of 10 categories who had visited a de
- Costs, Uncertainty May Cause Consumers to Delay Cosmetic Procedures: ASDShttps://practicaldermatology.com/news/costs-uncertainty-may-cause-consumers-to-delay-cosmetic-procedures-asds/2458886/Cost, fear of suboptimal results, and uncertainty over choosing a provider are the key concerns that may deter prospective patients from receiving cosmetic treatments, new findings from the 2015 American Society for Dermatologic Surgery Consumer Survey on Cosmetic Dermatologic Procedures sh
- Modernizing Medicine Reveals Telemedicine Component for its EMRhttps://practicaldermatology.com/news/modernizing-medicine-reveals-telemedicine-component-for-its-emr/2458890/Modernizing Medicine, Inc. revealed a new t
- Provectus Receives Patent for Investigational Melanoma Agent PV-10https://practicaldermatology.com/news/provectus-receives-patient-for-investigational-melanoma-agent-pv-10/2458891/Provectus Biopharmaceuticals, Inc. has received a patent from the US Patent and Trademark Office, protecting the use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver. Specifically, the patent covers the use of PV-10 in combination wit
- MEG 21 with Supplamine Now Available in Treatment Rooms with New Professional Size Dispensershttps://practicaldermatology.com/news/meg-21-with-supplamine-now-available-in-treatment-rooms-with-new-professional-size-dispensers/2458892/MEG 21 with Supplamine is a science-based company specializing in skin products for the face, neck, décolleté, and arms that uniquely remove toxic sugar from skin. Dynamis Skin Science, the parent company, was founded in 1997, based on the work of scientists initially working at Fox
- GW School of Medicine and Health Sciences Announces New Dermatology Residency Programhttps://practicaldermatology.com/news/gw-school-of-medicine-and-health-sciences-announces-new-dermatology-residency-program/2458895/The George Washington University (GW) School of Medicine and Health Sciences (SMHS) is pleased to announce a new dermatology residency program that began on July 1, 2015. This unique training experience is open to national and international medical students, who will learn to provide the
- Finacea Foam 15% Approved for Treatment of Inflammatory Papules and Pustules in Patients with Mild to Moderate Rosaceahttps://practicaldermatology.com/news/finacea-foam-15-approved-for-treatment-of-inflammatory-papules-and-pustules-in-patients-with-mild-to-moderate-rosacea/2458899/The FDA approved Finacea® (azelaic acid) Foam, 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. The approval is based on results from two pivotal clinical trials examining the efficacy and safety of Finacea® Foam com
- Almirall Completes Investment in Suneva Medicalhttps://practicaldermatology.com/news/almirall-completes-investment-in-suneva-medical/2458900/Barcelona-based Almirall, a global pharmaceutical company, has closed a $15 million in Series C equity investment in Suneva Medical, Inc., marketer of Bellafill®. This product i
- Organogenesis Launches PuraPly Wound Management Productshttps://practicaldermatology.com/news/organogenesis-launches-puraply-wound-management-products/2458905/Organogenesis Inc. launched its new PuraPly™ wound management products, including PuraPly Antimicrobial (PuraPly AM), the first FDA-cleared purified collagen matrix with polyhexamethylene biguanide hydrochloride (PHMB) antimicrobial agent. PuraPly and PuraPly AM are the la
- Novartis Combination Therapy Tafinlar and Mekinist Receives FDA Priority Review Designationhttps://practicaldermatology.com/news/novartis-combination-therapy-tafinlar-and-mekinist-receive-fda-priority-review-designation/2458904/The FDA has granted priority review for the same patient population for the combination of Novartis’ Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Also, the Committee for Medi